Human stem cells can develop genomic abnormalities, arising at a very low level of mosaicism. These defects need to be identified as quickly as possible in the process, as they can rapidly develop and overtake cell cultures. Their impact can be detrimental to the quality of the final product.
Sequencing technologies such as Next-Generation Sequencing (NGS) provide high detection power, helping research scientists to strengthen their workflows. However, the main constraint of this method is the vast amount of information it can generate. This turns result interpretation into a time consuming and challenging exercise for most teams.
This is what led Stem Genomics to design a targeted sequencing assay with fully interpreted results that mean something to you.
Watch a short video for a visual presentation of our latest NGS-targeted panel and discover the main benefits it offers scientists working on stem cells.
Based on innovative NGS technology, the Stem-Seq™ Panel enables scientists to look deeper into targeted regions of interest. This is particularly suited to pluripotent stem cell scientists who encounter the highest level of mutations in their cells.
The Stem-Seq™ Panel is a custom-made, targeted NGS panel composed of 361 genes that have been selected for their relevance to stem cell scientists. It detects Single-Nucleotide Variants (SNVs) associated with cancer (including TP53, BCOR, etc.) but also selected variants specific to pluripotent stem cells and their impact on the natural development of cells in culture.
Once sequencing has been completed, our expertise continues to add value to the end result. No need to have a team of in-house bioinformaticians or dedicate time for deciphering and interpreting results. Our specialists will analyze the data so you don’t have to. Thanks to the knowledge gathered in stem cells genomic integrity over the years, references to recognized databases and relevant publications, Stem Genomics is able to interpret your results based on what could potentially be pathogenic for your cells.
Meanwhile, you can remain focused on your research work.
All human cell types
Acquisition of a new line
End of process
4-5 weeks depending on report selection
Stem Genomics handles the whole process for you from receipt of DNA samples to the delivery of the results. The library is built using Twist capture technology and the sequencing is performed on Illumina NovaSeq as paired-end reads. The final analysis will be sent to you within 4-5 weeks depending on the level of reporting you need.
Follow the step-by-step guidance to perform your assay: view useful documents
Recommended guidelines on genomic stability advise checking cells at various key steps in the workflow. Due to its exhaustivity and strong technical performance, the Stem-Seq™ Panel is best suited for the acquisition stage, when banking cells and/or at the end of the workflow. It strengthens the RUO process overall and supports the application for entering the clinical stage.
Click on the graph for more details
Please enter your e-mail address.